Stand up for science

The biopharma industry has done itself no favors by staying on the sidelines for two months as FDA’s fate has been debated in the White House and Trump Tower. To the contrary, this duck and cover strategy has demonstrated that the industry is unwilling or unable to stand up and act with confidence on an issue of great importance.

Although a few CEOs publicly challenged ideas attributed to one of the most outrageous candidates for FDA commissioner, industry largely sat silent and hoped for the best. ...